Literature DB >> 17363562

MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.

Andrew D Slack1, Zaowen Chen, Andrew D Ludwig, John Hicks, Jason M Shohet.   

Abstract

The MYC family oncogenes cause transformation and tumor progression by corrupting multiple cellular pathways, altering cell cycle progression, apoptosis, and genomic instability. Several recent studies show that MYCC (c-Myc) expression alters DNA repair mechanisms, cell cycle checkpoints, and karyotypic stability, and this is likely partially due to alterations in centrosome replication control. In neuroblastoma cell lines, MYCN (N-Myc) expression induces centrosome amplification in response to ionizing radiation. Centrosomes are cytoplasmic domains that critically regulate cytokinesis, and aberrations in their number or structure are linked to mitotic defects and karyotypic instability. Whereas centrosome replication is linked to p53 and Rb/E2F-mediated cell cycle progression, the mechanisms downstream of MYCN that generate centrosome amplification are incompletely characterized. We hypothesized that MDM2, a direct transcriptional target of MYCN with central inhibitory effects on p53, plays a role in MYC-mediated genomic instability by altering p53 responses to DNA damage, facilitating centrosome amplification. Herein we show that MYCN mediates centrosome amplification in a p53-dependent manner. Accordingly, inhibition of the p53-MDM2 interaction with Nutlin 3A (which activates p53) completely ablates the MYCN-dependent contribution to centrosome amplification after ionizing radiation. We further show that modulating MDM2 expression levels by overexpression or RNA interference-mediated posttranscriptional inhibition dramatically affects centrosome amplification in MYCN-induced cells, indicating that MDM2 is a necessary and sufficient mediator of MYCN-mediated centrosome amplification. Finally, we show a significant correlation between centrosome amplification and MYCN amplification in primary neuroblastoma tumors. These data support the hypothesis that elevated MDM2 levels contribute to MYCN-induced genomic instability through altered regulation of centrosome replication in neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363562     DOI: 10.1158/0008-5472.CAN-06-1661

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Suppression of Aurora-A oncogenic potential by c-Myc downregulation.

Authors:  Shangbin Yang; Shun He; Xiaobo Zhou; Mei Liu; Hongxia Zhu; Yihua Wang; Wei Zhang; Shuang Yan; Lanping Quan; Jingfeng Bai; Ningzhi Xu
Journal:  Exp Mol Med       Date:  2010-11-30       Impact factor: 8.718

2.  Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.

Authors:  Xiang Zhao; Dan Li; Feng Yang; Heng Lian; Jianqun Wang; Xiaojing Wang; Erhu Fang; Huajie Song; Anpei Hu; Yanhua Guo; Yang Liu; Hongjun Li; Yajun Chen; Kai Huang; Liduan Zheng; Qiangsong Tong
Journal:  Mol Ther       Date:  2020-01-11       Impact factor: 11.454

3.  N-Myc and L-Myc are essential for hair cell formation but not maintenance.

Authors:  Benjamin J Kopecky; Rhonda Decook; Bernd Fritzsch
Journal:  Brain Res       Date:  2012-09-25       Impact factor: 3.252

4.  Tripeptidyl Peptidase II Is Required for c-MYC-Induced Centriole Overduplication and a Novel Therapeutic Target in c-MYC-Associated Neoplasms.

Authors:  Stefan Duensing; Sebastian Darr; Rolando Cuevas; Nadja Melquiot; Anthony G Brickner; Anette Duensing; Karl Münger
Journal:  Genes Cancer       Date:  2010-09

5.  Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.

Authors:  Marc J Rigatti; Rajeev Verma; Glenn S Belinsky; Daniel W Rosenberg; Charles Giardina
Journal:  Mol Carcinog       Date:  2011-05-06       Impact factor: 4.784

6.  p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer.

Authors:  Susan M Mendrysa; Sara Ghassemifar; Reem Malek
Journal:  Genes Cancer       Date:  2011-04

7.  Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO.

Authors:  Jennifer L Alabran; Adam Cheuk; Karen Liby; Michael Sporn; Javed Khan; John Letterio; Konstantin S Leskov
Journal:  Cancer Biol Ther       Date:  2008-05-07       Impact factor: 4.742

Review 8.  A clinical overview of centrosome amplification in human cancers.

Authors:  Jason Yongsheng Chan
Journal:  Int J Biol Sci       Date:  2011-10-16       Impact factor: 6.580

9.  Combining chromosomal arm status and significantly aberrant genomic locations reveals new cancer subtypes.

Authors:  Tal Shay; Wanyu L Lambiv; Anat Reiner-Benaim; Monika E Hegi; Eytan Domany
Journal:  Cancer Inform       Date:  2009-03-12

10.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.